To include your compound in the COVID-19 Resource Center, submit it here.

Emibetuzumab: Phase II data

Data from 89 evaluable c-MET-positive, metastatic NSCLC patients with acquired resistance to Tarceva in an open-label, international Phase II

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE